Galmed Pharmaceuticals (FRA:GPH) Cyclically Adjusted FCF per Share: €-829.34 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:GPH Galmed Pharmaceuticals Ltd FRA:GPH
29 GF Score
Price €2.74
! 2 Warning Signs
View Full Analysis

What is Galmed Pharmaceuticals Cyclically Adjusted FCF per Share?

Galmed Pharmaceuticals FRA:GPH 29 Cyclically Adjusted FCF per Share is €-829.34 as of Mar. 2026. GuruFocus rates FRA:GPH with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Galmed Pharmaceuticals's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.333. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-829.34 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 6.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Galmed Pharmaceuticals was 6.20% per year. The lowest was 6.20% per year. And the median was 6.20% per year.

As of today (2026-07-25), Galmed Pharmaceuticals's current stock price is €2.736. Galmed Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-829.34. Galmed Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


Galmed Pharmaceuticals  (FRA:GPH) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Galmed Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


Galmed Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Galmed Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galmed Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Galmed Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -142.13 -155.68 -143.14 -555.95

Galmed Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -312.06 -240.28 -312.76 -555.95 -829.34

FRA:GPH vs FBLG, SXTP, CELZ: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Galmed Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galmed Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galmed Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Galmed Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


FRA:GPH
29GF Score
Galmed Pharmaceuticals Ltd FRA:GPH
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galmed Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Galmed Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.333/330.2130*330.2130
=-0.333

Current CPI (Mar. 2026) = 330.2130.

Galmed Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -43.468 241.018 -59.554
201609 -46.210 241.428 -63.204
201612 -39.235 241.432 -53.663
201703 -53.368 243.801 -72.284
201706 -36.853 244.955 -49.680
201709 -35.217 246.819 -47.116
201712 -28.781 246.524 -38.551
201803 -35.138 249.554 -46.495
201806 -14.241 251.989 -18.662
201809 -14.138 252.439 -18.494
201812 -17.188 251.233 -22.591
201903 -28.940 254.202 -37.594
201906 -24.068 256.143 -31.028
201909 -30.060 256.759 -38.660
201912 -31.299 256.974 -40.219
202003 -50.525 258.115 -64.638
202006 -47.068 257.797 -60.290
202009 -40.339 260.280 -51.177
202012 -53.692 260.474 -68.067
202103 -60.008 264.877 -74.810
202106 -45.612 271.696 -55.436
202109 -54.957 274.310 -66.157
202112 -44.511 278.802 -52.719
202203 -35.612 287.504 -40.902
202206 -40.230 296.311 -44.833
202209 -22.464 296.808 -24.992
202212 -27.136 296.797 -30.191
202303 -11.227 301.836 -12.283
202306 -9.014 305.109 -9.756
202309 -3.916 307.789 -4.201
202312 -1.960 306.746 -2.110
202403 -2.770 312.332 -2.929
202406 -1.394 314.175 -1.465
202409 -1.222 315.301 -1.280
202412 -1.094 315.605 -1.145
202503 -0.599 319.799 -0.619
202506 -0.278 322.561 -0.285
202509 -0.302 324.800 -0.307
202512 -0.276 324.054 -0.281
202603 -0.333 330.213 -0.333

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-829.34 mean?
Galmed Pharmaceuticals (FRA:GPH) has a Cyclically Adjusted FCF per Share of €-829.34 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Galmed Pharmaceuticals and its competitors.
Is Galmed Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
Galmed Pharmaceuticals' current Cyclically Adjusted FCF per Share is €-829.34. Overall, Galmed Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Galmed Pharmaceuticals' Cyclically Adjusted FCF per Share compare to FBLG and SXTP?
Galmed Pharmaceuticals' Cyclically Adjusted FCF per Share of €-829.34 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Galmed Pharmaceuticals and its competitors. Galmed Pharmaceuticals's current Cyclically Adjusted FCF per Share is €-829.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galmed Pharmaceuticals stock overvalued right now?
Galmed Pharmaceuticals (FRA:GPH) has a current Cyclically Adjusted FCF per Share of €-829.34. The current Cyclically Adjusted FCF per Share is €-829.34. Galmed Pharmaceuticals' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Galmed Pharmaceuticals (FRA:GPH), the current Cyclically Adjusted FCF per Share is €-829.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galmed Pharmaceuticals Business Description

Other Exchanges GLMD:USA
Address c/o Meitar Law Offices, 16 Abba Hillel Road, Ramat Gan, ISR, 5250608
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
29GF Score

Get the complete analysis for FRA:GPH

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.74
Price